Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)
Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Micardis® (Drug); MicardisPlus® (Drug)
Phase: N/A
Status: Completed
Sponsored by: Boehringer Ingelheim
Summary
Study to evaluate efficacy and tolerability of Micardis®/MicardisPlus® under usual
daily-practice prescribing-conditions with emphasis on effects on endorgan damage in the
clientele of cardiologists, nephrologists, and diabetologists
Clinical Details
Official title: Micardis® / MicardisPlus® PROTEKT (Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases)
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Change in systolic blood pressure (SBP)Change in diastolic blood pressure (DBP)
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age >= 18 years
Exclusion Criteria:
- Age < 18 years
Locations and Contacts
Additional Information
Starting date: September 2003
Last updated: October 10, 2014
|
